CGON

CG Oncology (CGON)

About CG Oncology (CGON)

CG Oncology, Inc. is a clinical biopharmaceutical company, which engages in the development and commercialization of bladder-sparing therapeutic for patients afflicted with bladder cancer. It offers cretostimogene, a product initially in clinical development for the treatment of patients with Non-Muscle Invasive Bladder Cancer (NMIBC). The company was founded by Alex Yeung and Paul A. DeRidder on September 24, 2010 and is headquartered in Irvine, CA.

Details

Daily high
$66.81
Daily low
$63.50
Price at open
--
52 Week High
$66.81
52 Week Low
$14.80
Market cap
5.6B
Dividend yield
0.00%
Volume
2,344
Avg. volume
1.3M
P/E ratio
-31.65

CG Oncology News

Details

Daily high
$66.81
Daily low
$63.50
Price at open
--
52 Week High
$66.81
52 Week Low
$14.80
Market cap
5.6B
Dividend yield
0.00%
Volume
2,344
Avg. volume
1.3M
P/E ratio
-31.65